99 related articles for article (PubMed ID: 27701987)
21. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
23. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
[TBL] [Abstract][Full Text] [Related]
24. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
25. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
26. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
27. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
28. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
30. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.
Ji N; Mukherjee N; Reyes RM; Gelfond J; Javors M; Meeks JJ; McConkey DJ; Shu ZJ; Ramamurthy C; Dennett R; Curiel TJ; Svatek RS
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653802
[TBL] [Abstract][Full Text] [Related]
33. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
34. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
[TBL] [Abstract][Full Text] [Related]
35. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
[TBL] [Abstract][Full Text] [Related]
36. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
Enatsu N; Ota T; Ochi A
Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
[No Abstract] [Full Text] [Related]
37. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
38. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of Nestin expression in pT1 high- grade bladder urothelial carcinoma patients treated with intravesical BCG.
Sen V; Bozkurt O; Demir O; Tuna B; Yorukoglu K; Ellidokuz H; Mungan U
Asian Pac J Cancer Prev; 2014; 15(24):10813-7. PubMed ID: 25605182
[TBL] [Abstract][Full Text] [Related]
40. Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation.
Misra S; Gupta A; Symes A; Duncan J
Scand J Urol; 2014 Jun; 48(3):328-30. PubMed ID: 24070063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
